Last updated 2026-07-27
TL;DR
Sirolimus (rapamycin) is FDA-approved only for organ transplant rejection and two rare conditions (LAM, facial angiofibromas). Using it for longevity or anti-aging is entirely off-label, though legal in the US with a valid prescription. No compounding pharmacy, telehealth clinic, or supplement seller can legally sell it without one, and there is still no completed human lifespan trial to back the practice.
Is sirolimus legal to take in the United States?
Yes, sirolimus is legal in the US, but only as a prescription drug. It's a Schedule-free, non-controlled medication, meaning the DEA doesn't restrict it the way it restricts opioids or stimulants. That's the good news for anyone curious about it. The catch is that "legal" and "approved for what you want to use it for" are two different things. The FDA approved the original sirolimus tablet (brand name Rapamune) in 1999 to prevent organ rejection after kidney transplants [1]. Since then, related formulations have been approved for narrow, specific conditions: Fyarro (albumin-bound sirolimus, nab-sirolimus) for a rare soft-tissue sarcoma called malignant perivascular epithelioid cell tumor, and Hyftor, a topical sirolimus gel for facial angiofibromas linked to tuberous sclerosis complex [2] [3]. None of those approvals mention aging, lifespan, or healthspan. So if you're getting sirolimus from a US-licensed physician who writes a legitimate prescription, and a licensed pharmacy dispenses it, you are operating entirely within the law. What you can't do legally is buy it without a prescription, order it from an unlicensed overseas source and import it for personal use at scale, or have a business market it directly to consumers as an anti-aging treatment without a doctor in the loop.
What is sirolimus actually FDA-approved to treat?
Sirolimus has three FDA-approved uses, and every one of them is about disease, not longevity. First is prophylaxis of organ rejection in kidney transplant patients aged 13 and older, the original 1999 indication for Rapamune [1]. Second is Fyarro, approved in 2021 for adults with locally advanced or metastatic malignant PEComa, a rare cancer [2]. Third is Hyftor, a 0.15% topical gel approved in 2022 for facial angiofibromas in patients 6 and older with tuberous sclerosis complex [3]. That's the entire approved label. There is no FDA indication for aging, longevity, healthspan extension, or prevention of age-related disease in otherwise healthy adults. Any clinician prescribing it for that purpose is prescribing off-label, which is legal in the US (physicians have wide latitude to prescribe approved drugs for unapproved uses) but it means the safety and efficacy data you're leaning on for the longevity use case did not come from FDA review of that use case. The FDA's own guidance on off-label use is blunt about where the responsibility sits: physicians decide off-label use "based on their medical judgment," not on the agency's assessment of that specific use. In other words, nobody at the FDA has looked at intermittent low-dose sirolimus for a 45-year-old who wants to live longer and said this is safe and effective. That determination, for this use, doesn't exist yet.
What is the actual longevity evidence, and is it human or animal?
The strongest sirolimus longevity data is in mice, not people, and the gap matters more than almost anything else in this story. The National Institute on Aging's Interventions Testing Program (ITP), a multi-site, NIH-funded effort designed specifically to find compounds that extend mouse lifespan with rigorous replication, has tested rapamycin repeatedly since 2006. Results have been consistent: rapamycin extends median lifespan in genetically heterogeneous mice, in both sexes, even when started relatively late in life [4]. One widely cited ITP result found that rapamycin fed starting at 600 days of age (roughly equivalent to late middle age in humans) still extended lifespan, with effects more pronounced in females in some cohorts [4]. Other ITP-associated work has shown dose-dependent effects and benefits even at lower doses than originally tested [5]. Here's the part that gets lost in longevity marketing: there is no completed randomized controlled trial showing sirolimus extends human lifespan or meaningfully improves healthspan in healthy people. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), a crowdfunded, decentralized trial run out of Harvard and elsewhere, has published only interim and safety-focused findings on quality-of-life and safety measures over 48 weeks in adults aged 50-85, not lifespan or hard endpoint data . It's a real trial with real people, and it's a meaningful start. It is not proof of a lifespan benefit in humans, and nobody running it claims that it is. So the honest state of the science, as of now: mouse data is genuinely strong and reproducible across an unusually rigorous testing program. Human data is limited to short safety and biomarker studies. Nobody has run a trial long enough, large enough, or with the right endpoints to say sirolimus extends human life. That gap is the whole story, and any framing that skips it is selling you something.
Is rapamycin the same thing as sirolimus, legally and chemically?
Yes. Rapamycin and sirolimus are the same molecule; sirolimus is the generic drug name, and rapamycin is the name derived from its discovery in soil bacteria (Streptomyces hygroscopicus) found on Rapa Nui (Easter Island) in the 1970s . When you see a prescription bottle, it will say sirolimus. When you read longevity research or podcasts, people usually say rapamycin. Same drug, same molecule, same FDA regulatory status. This matters for the legal conversation because there's no gray-market loophole where "rapamycin" is somehow less regulated than "sirolimus." Some companies have tried to market rapamycin-adjacent products (topical creams, supplements claiming rapamycin-like effects) without it actually being the prescription drug, and those are a different, much murkier legal category worth being suspicious of. If a product actually contains sirolimus/rapamycin at a pharmacologically active dose, it is a prescription drug in the US, full stop, regardless of which name is on the label.
Can I buy sirolimus without a prescription in the US?
No, not legally. Sirolimus is not available over the counter anywhere in the United States. Every FDA-approved formulation, Rapamune tablets and oral solution, Fyarro, Hyftor, requires a prescription from a licensed prescriber [1] [2] [3]. Any US-based seller offering it without one is operating outside the law, and any product claiming to be "research-grade" sirolimus sold to consumers without a prescription requirement is a red flag, both legally and for basic quality control. That doesn't mean getting a prescription is hard. A growing number of telehealth and longevity-focused clinics now offer off-label sirolimus prescribing after a consultation and, ideally, baseline labs. That's a legitimate legal path: a licensed physician evaluates you, decides the off-label use is appropriate for your situation, and writes a prescription that a licensed pharmacy fills. What separates a legitimate operation from a sketchy one usually comes down to whether there's an actual clinician reviewing your case, whether they ask about contraindications and check labs, and whether the pharmacy filling it is licensed and provider-reviewed rather than an anonymous overseas supplier.
Do I need a doctor's prescription, or can a longevity clinic just sell it to me?
You need a prescription either way. A "longevity clinic" is not a separate legal category that bypasses prescription requirements; it's simply a clinical practice, and any sirolimus it provides has to come through a licensed prescriber writing an actual prescription, filled by a licensed pharmacy. The FDA's Federal Food, Drug, and Cosmetic Act requires prescription-only drugs to be dispensed only pursuant to a valid prescription from a practitioner licensed to do so . What varies is the quality of the process behind that prescription. Some clinics do a real intake: medical history, current medications (interaction risk matters here), sometimes labs like lipid panels and white blood cell counts before and during use. Others are closer to a rubber stamp, a quick online form and a prescription within minutes. Both are technically legal if a licensed physician's name is actually attached and they're exercising some judgment, but only one of those approaches is good medicine. Given that this is an off-label use with a real but still-unresolved risk profile, a provider-reviewed process that actually screens you (and stays reachable if you have side effects) is worth more than convenience.
What are the real risks: immunosuppression, mouth ulcers, and metabolic effects?
This is where the legal question and the medical question overlap, because the FDA's approved label risks come from transplant-dose use, not the lower, intermittent doses common in off-label longevity protocols, and that difference matters but doesn't eliminate the risks. Immunosuppression is the headline risk. Sirolimus works by inhibiting mTOR, a pathway central to both cell growth and immune cell proliferation, which is exactly why it prevents transplant rejection and exactly why it can blunt your immune response. At transplant doses, the FDA label lists increased risk of infection and certain cancers (particularly lymphoma and skin cancer) as major concerns [1]. At the lower, often once-weekly doses used in off-label longevity protocols, the immunosuppressive effect is thought to be smaller, but there is no large, long-term human safety dataset confirming that intermittent low-dose use is free of meaningful immune suppression. It's a plausible, mechanism-based hope, not a settled fact. Mouth ulcers (stomatitis) are the single most commonly reported side effect in both transplant patients and in the small human longevity-adjacent studies. In trials of sirolimus in transplant patients, stomatitis was reported in roughly a third of patients at some dose levels [1]. Interim safety data from PEARL-type dosing regimens has also flagged mouth sores as a frequent, dose-related complaint, generally manageable but common enough that people should expect it . Metabolic effects are the third bucket. Sirolimus can raise triglycerides and LDL cholesterol, and can affect blood glucose and insulin sensitivity in some people, effects well documented in the transplant literature [1]. Some longevity users report the opposite (improved metabolic markers) in small, self-reported cohorts, but it cuts both ways and should be tracked with actual bloodwork, not assumed. Other less common but real concerns from the approved label include delayed wound healing, elevated risk of certain infections, and lung issues (interstitial lung disease has been reported, more often at higher, sustained doses) [1]. None of this means low-dose intermittent sirolimus is dangerous for a healthy adult. It means the risk profile at longevity doses is extrapolated from transplant data and small human trials, not from a dedicated large safety trial in healthy people, and anyone using it should be doing so under a provider who checks labs periodically.
What does 'off-label' actually mean, and is it risky legally for the prescribing doctor?
Off-label means a doctor is prescribing an FDA-approved drug for a use, population, or dose the FDA hasn't specifically approved. It's legal, common, and happens across huge swaths of medicine (a lot of pediatric dosing, psychiatric prescribing, and cancer treatment is off-label). The FDA has stated plainly that it "does not regulate the practice of medicine" and that healthcare providers may prescribe FDA-approved drugs for unapproved uses when they judge it medically appropriate. What's not legal is a company making unsubstantiated marketing claims that a drug treats or prevents a disease it isn't approved for. That's why you'll notice legitimate sirolimus prescribers and pharmacy partners talk carefully about "off-label use for longevity purposes under physician supervision" rather than claiming it "reverses aging" or "extends lifespan" as a marketing promise. The FDA has sent warning letters to companies over unsupported anti-aging drug claims before, and that regulatory risk sits with the marketer, not with an individual physician exercising off-label prescribing judgment for a specific patient.
Where does an actual prescription for longevity-dose sirolimus come from?
It starts with a licensed physician, whether that's your regular PCP (many aren't familiar with off-label longevity dosing yet), a specialist interested in longevity medicine, or a telehealth platform that specifically offers this consultation. From there, the prescription goes to a licensed pharmacy, often a compounding pharmacy, since standard commercial sirolimus tablets come in fixed doses (0.5mg, 1mg, 2mg) that don't always match the intermittent, once-weekly regimens common in longevity protocols [1]. Sirolimus Rx works with a provider-reviewed model: a clinician evaluates your case and, where appropriate, issues a prescription that's filled through a named, licensed pharmacy partner, not sold directly as a product. That structure exists precisely because of the legal reality above, prescription-only status, off-label use, no shortcut around a real clinical evaluation. If you're comparing options, the two practical questions to ask any provider are: who is the licensed physician reviewing my case, and which licensed pharmacy is actually dispensing the drug. If either answer is vague, that's a signal to look elsewhere. For readers ready to move from research to logistics, the practical next steps live in dosing: how sirolimus dosage is typically structured for off-label use, how to use a dosage calculator to think through weight-based dosing questions with your provider, and the mechanics of reconstitution and injection if your specific formulation requires it.
How does sirolimus's legal status compare to other longevity compounds people ask about?
| Sirolimus/rapamycin | Approved for transplant rejection, PEComa (Fyarro), facial angiofibromas (Hyftor) [1] [2] [3] | No, prescription only | No | |
|---|---|---|---|---|
| Metformin | Approved for type 2 diabetes | No, prescription only | No (TAME trial still seeking funding as of recent updates) | |
| NAD+ precursors (NMN, NR) | Not FDA-approved as drugs; sold as supplements | Yes, as dietary supplements | No | |
| Resveratrol | Not FDA-approved as a drug; sold as supplement | Yes, as dietary supplement | No | The practical difference: supplements like NMN or resveratrol are regulated under the Dietary Supplement Health and Education Act (DSHEA), meaning a company can sell them without proving efficacy for any specific condition, only without making disease claims. Sirolimus has no such path. It's a prescription drug with an approved label that doesn't include longevity, so there's no legal way to sell it over the counter regardless of how strong the mouse data is [4]. That stricter framework is arguably a feature, not a bug: it forces a physician into the loop, which matters given the real, if likely modest at low doses, immunosuppression and metabolic risk discussed above. |
Sirolimus sits in a stricter legal category than most other things labeled "longevity supplements," and that's worth understanding clearly. | Compound | FDA status | Legal to buy OTC? | Human lifespan trial completed? |
What should I actually do with this information?
If you're a longevity-focused researcher or a careful early adopter, here's the honest bottom line. The mouse data from the NIA's Interventions Testing Program is some of the most rigorously replicated lifespan-extension data that exists for any compound, tested across multiple independent labs with pre-registered protocols [4]. That's genuinely rare and genuinely impressive as animal science. The human data, however, is thin. No completed trial has shown sirolimus extends human lifespan or definitively improves healthspan; the best we have is interim safety and quality-of-life signal from small trials like PEARL . Anyone telling you the human case is closed is overstating the evidence. Legally, your path is straightforward even if the science isn't settled: get evaluated by a licensed physician, get a real prescription if they judge it appropriate for you, fill it through a licensed pharmacy, and get periodic labs (lipids, blood counts, kidney function) while you're on it. Skip anyone selling it without that structure. Given the real risks around immune function, mouth ulcers, and lipid changes, this isn't a compound to self-source from an unregulated supplier no matter how compelling the mouse data looks.
Frequently asked questions
Is sirolimus FDA-approved for anti-aging or longevity?
No. Sirolimus is FDA-approved only to prevent organ transplant rejection, treat a rare cancer (PEComa, as Fyarro), and treat facial angiofibromas from tuberous sclerosis (as Hyftor gel) [1][2][3]. Any use for aging, lifespan, or healthspan is entirely off-label, meaning a physician is prescribing it beyond its approved indication based on their own clinical judgment, not FDA review.
Is it legal to buy sirolimus online without a prescription?
No. Sirolimus is a prescription-only drug in the United States under the Federal Food, Drug, and Cosmetic Act's prescription drug provisions [9]. Any site selling it without requiring a valid prescription from a licensed physician is operating illegally, and the product's quality and sourcing can't be verified the way a licensed pharmacy's can.
What's the difference between sirolimus and rapamycin?
None chemically. They're the same molecule; sirolimus is the generic drug name and rapamycin is its original name, derived from Rapa Nui (Easter Island), where the soil bacterium that produces it was discovered [8]. Prescriptions and pharmacy labels use sirolimus; longevity research and media typically say rapamycin.
Has any human trial shown sirolimus extends lifespan?
No completed trial has shown this. The mouse evidence from the NIA's Interventions Testing Program is strong and repeatedly replicated [5]. In humans, the PEARL trial has published interim safety and quality-of-life data over 48 weeks but no lifespan or long-term healthspan outcome data [7]. That gap is the central open question in the field.
What are the main risks of off-label sirolimus use for longevity?
The three most documented risks are immunosuppression (increased infection risk, mechanism-based even at low doses), mouth ulcers/stomatitis (reported in roughly a third of transplant-dose patients and commonly in lower-dose regimens too) [1][7], and metabolic effects including raised triglycerides and LDL cholesterol [1]. Regular labs and physician oversight are how these are monitored.
Can my regular doctor prescribe sirolimus for longevity purposes?
Legally, yes, any licensed physician can prescribe an approved drug off-label if they judge it clinically appropriate [4]. Practically, many primary care doctors aren't familiar with longevity dosing protocols or monitoring schedules, which is why many patients use telehealth clinics or longevity-focused practices with physicians experienced in this specific off-label use.
Does the FDA regulate off-label prescribing?
The FDA regulates drug approval and manufacturer marketing claims, but has stated it "does not regulate the practice of medicine," leaving off-label prescribing decisions to individual physicians' medical judgment [4]. What the FDA does police is companies making unapproved disease claims in marketing, which is separate from a doctor's prescribing decision.
Is sirolimus a controlled substance?
No. Sirolimus is not scheduled under the Controlled Substances Act. It's a standard prescription-only drug, similar in regulatory category to many other non-narcotic prescription medications, not subject to DEA scheduling restrictions the way opioids or stimulants are.
What is the NIA Interventions Testing Program, and why does it matter here?
The Interventions Testing Program (ITP) is an NIH National Institute on Aging-funded, multi-site study designed to test compounds for lifespan effects in genetically diverse mice with rigorous, replicated protocols. Rapamycin is its most consistent positive finding, extending median lifespan in both sexes across multiple cohorts and even when started later in life [5].
Are there FDA-approved topical or gel forms of sirolimus?
Yes. Hyftor is an FDA-approved 0.15% topical sirolimus gel, approved in 2022 for facial angiofibromas associated with tuberous sclerosis complex in patients 6 and older [3]. It is not approved or studied for cosmetic anti-aging use on skin generally.
What's Fyarro, and is it the same as regular sirolimus?
Fyarro (nab-sirolimus) is an albumin-bound formulation of sirolimus, FDA-approved in 2021 for adults with advanced malignant PEComa, a rare sarcoma [2]. It's the same active molecule as sirolimus/rapamycin but formulated differently for cancer treatment; it isn't used or studied for longevity dosing.
Why do some longevity protocols use once-weekly dosing instead of daily?
Intermittent, often weekly, dosing is based on the theory that pulsed mTOR inhibition can capture longevity-related benefits seen in mouse studies while limiting the sustained immunosuppression associated with the continuous daily dosing used in transplant medicine. This regimen hasn't been validated in a completed human lifespan trial; it's an extrapolation from mechanism and animal data, discussed further in sirolimus dosage and cycle length guidance.
Can I get in legal trouble for taking sirolimus off-label myself?
No, patients aren't legally at risk for using a legally prescribed drug off-label; that's a routine, legal part of medical practice in the US. The legal exposure sits with sellers making false disease claims or dispensing without a valid prescription, not with a patient following their physician's prescribed off-label regimen.
Sources
- FDA, Understanding Unapproved Use of Approved Drugs 'Off Label': FDA does not regulate the practice of medicine; physicians determine off-label use based on medical judgment
- NIA Interventions Testing Program, rapamycin lifespan findings (Harrison et al., Nature): Rapamycin extends median lifespan in genetically heterogeneous mice across multiple independent test sites, including when started later in life
- Miller et al., Journals of Gerontology, rapamycin dose-response in mice: Rapamycin shows dose-dependent lifespan extension effects in mice, including at lower doses
- NIH National Cancer Institute, Drug Dictionary: sirolimus: Sirolimus (rapamycin) is derived from a bacterium discovered on Rapa Nui (Easter Island)
- U.S. Code, Federal Food, Drug, and Cosmetic Act, prescription drug dispensing requirements: Prescription drugs may only be dispensed pursuant to a valid prescription from a licensed practitioner